BioLineRx (BLRX) Announces Completion of BL-8040 Phase 1 Dose Escalations
Tweet Send to a Friend
BioLineRx (NASDAQ: BLRX) has completed the dose escalation stage of a Phase 1 trial for its novel oncology platform, BL-8040 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
